In this article/podcast from KevinMD.com, Dr. Kristin Yates, an OB/GYN, describes her work as a doctor, which “brings me fulfillment and joy. It makes me a better doctor.” Dr. Yates also explains: “The fact of the matter is, I am not a doctor. I am a human being. Doctoring is what I do, not who I am. This distinction is very important to me because it is what has made medicine sustainable and fulfilling.”

The 27-member petition, which is led by Dr. Linda Wastila, a professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, calls the notion of approval to stimulate vaccination rates “backward logic.” The group of clinicians and researchers claim data should be from completed phase III trials, not interim results. “Slow down and get the science right,” the group wrote in a blog post published in The British Medical Journal.

We’ve all experienced a memory blip now and then, but these so-called “senior moments” could actually be signaling a bigger problem. Alzheimer’s disease (AD) is not a normal part of aging even though aging ups the risk for developing the condition. Here are 10 warning signs you can share with patients if they’re questioning what’s normal memory behavior and what’s not.  

The investigational new drug (IND) application is for GDX012, which also received an FDA orphan drug designation for the treatment of acute myeloid leukemia (AML). The drug’s manufacturer, GammaDelta Therapeutics, is developing the T-cell platform in partnership with Takeda and will initiate a phase I study in late 2021 that will evaluate the treatment’s safety and activity in patients with measurable residual disease-positive AML.

In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially high CV disease risk has increased.

An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.